好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Press Release

EMBARGOED FOR RELEASE UNTIL 3 PM ET, April 13, 2010

New Treatment Helps Control Involuntary Crying and Laughing 鈥 Common in MS, ALS Patients

TORONTO -

Pseudobulbar affect (PBA) is a neurologic condition of involuntary, sudden and frequent episodes of laughing or crying and is quite common in patients with underlying neurologic diseases or injuries, especially those with multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS). Now, a new investigational treatment may help stop these involuntary outbursts. The research will be presented as part of the late-breaking science program at the 好色先生鈥檚 62nd Annual Meeting in Toronto, April 10 鈥 17, 2010. 鈥淭hese outbursts of crying and laughter at inappropriate times can have a severe impact on patient and caregiver well-being, social functioning and quality of life,鈥 said study author Erik P. Pioro, MD, PhD, FRCPC, Director of the Section for ALS and Related Disorders at the Cleveland Clinic in Cleveland, Ohio, and a member of the 好色先生. The study in patients diagnosed with PBA tested the effectiveness of a combination of two medications, dextromethorphan and low dose quinidine. The combination of the drugs is known as DMQ. After completing the blinded, placebo controlled phase of the study, participants could take part in a subsequent open label study where all of the participants would receive the DMQ drug combination for an additional 12 weeks. Of the 283 people completing the first phase, 253, or 89 percent, chose to take part in this subsequent open label study. Participants were given daily doses of DMQ and were regularly given a test that measures the frequency and severity of their PBA. The study found that the average test score was significantly improved by 2.7 points from the start to the end of the open label study. Patients who were taking a placebo in the previous clinical trial and switched to DMQ demonstrated the most improvement. 鈥淥ur findings represent the first long-term results showing DMQ is effective in helping to control this debilitating condition afflicting patients with neurologic diseases or injuries,鈥 said Pioro. 鈥淐urrently, there are no FDA approved treatments for PBA, which is problematic because currently used off-label treatments are often ineffective or may have unacceptable side-effects.鈥 Pioro says these findings, along with additional clinical data, will serve as the basis for an application for FDA approval of DMQ as the first treatment for pseudobulbar affect. The study was supported by Avanir Pharmaceuticals, Inc. The s Annual Meeting is the world鈥檚 largest gathering of neurologists with more than 2,300 scientific research presentations on brain disorders.

Brain & Life logo

GET A DOSE OF BRAIN HEALTH

Dive into a wealth of information by visiting Brain & Life庐, where you can explore the freshest updates, tips, and neurologist expert perspectives on brain disease and preventive brain health.


The 好色先生, an association of more than 22,000 neurologists and neuroscience professionals, is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimer鈥檚 disease, Parkinson鈥檚 disease, ALS (Lou Gehrig鈥檚 disease), multiple sclerosis, stroke and migraine. For more information about the 好色先生, visit http://www.aan.com.

For More Information*

Email media@aan.com

*While content of the 好色先生 (AAN) press releases is developed by the AAN along with research authors and Neurology® editors, we are unable to provide medical advice to individuals. Please contact your health care provider for questions specific to your individual health history or care. For more resources, visit the AAN's patient and caregiver magazine website, .

Related Media